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Abstract
Background To date, the cerebral physiologic consequences of persistently elevated intracranial pressure (ICP) have been based
on either low-resolution physiologic data or retrospective high-frequency data from single centers. The goal of this study was to
provide a descriptive multi-center analysis of the cerebral physiologic consequences of ICP, comparing those with normal ICP to
those with elevated ICP.
Methods The Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) High-
Resolution Intensive Care Unit (HR-ICU) sub-study cohort was utilized. The first 3 days of physiologic recording were analyzed,
evaluating and comparing those patients with mean ICP < 15 mmHg versus those with mean ICP > 20 mmHg. Various cerebral
physiologic parameters were derived and evaluated, including ICP, brain tissue oxygen (PbtO2), cerebral perfusion pressure
(CPP), pulse amplitude of ICP (AMP), cerebrovascular reactivity, and cerebral compensatory reserve. The percentage time and
dose above/below thresholds were also assessed. Basic descriptive statistics were employed in comparing the two cohorts.
Results 185 patients were included, with 157 displaying a mean ICP below 15 mmHg and 28 having a mean ICP above
20 mmHg. For admission demographics, only admission Marshall and Rotterdam CT scores were statistically different between
groups (p = 0.017 and p = 0.030, respectively). The high ICP group displayed statistically worse CPP, PbtO2, cerebrovascular
reactivity, and compensatory reserve. The high ICP group displayed worse 6-month mortality (p < 0.0001) and poor outcome
(p = 0.014), based on the Extended Glasgow Outcome Score.
Conclusions Low versus high ICP during the first 72 h after moderate/severe TBI is associated with significant disparities in CPP,
AMP, cerebrovascular reactivity, cerebral compensatory reserve, and brain tissue oxygenation metrics. Such ICP extremes
appear to be strongly related to 6-month patient outcomes, in keeping with previous literature. This work provides multi-
center validation for previously described single-center retrospective results.
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Introduction
Intracranial pressure (ICP) has long been the focus of the
critical care management in moderate/severe traumatic brain
injury (TBI) patients. Consensus-based treatment guidelines
in TBI care, such as those from the Brain Trauma Foundation
(BTF), have gone through various renditions over the years,
with shifting focus on ICP and cerebral perfusion pressure
(CPP) thresholds [6]. Current guidelines suggest considering
an ICP threshold for treatment at 20 or 22.5 mmHg while
maintaining CPP between 60 and 70 mmHg [6, 16].
Various retrospective studies over the past few decades
have sought to describe cerebral physiologic phenomena of
elevations in ICP [1, 3, 8, 9, 11, 14]. Data from such prelim-
inary work supports the association between persistently ele-
vated ICP and mortality at 6 months post-TBI. [6, 14, 24]
Similarly, persistent ICP elevations have been shown to be
potentially linked to lower CPP values, [6] worse compensa-
tory reserve, [5, 34] impaired cerebrovascular reactivity, [1,
10, 14] lower PbtO2 values, [16, 22] and autonomic dysfunc-
tion, [15, 26] in those rare data sets with high-frequency dig-
ital physiology. However, most studies have suffered from
several limitations. One major criticism is that such work
has arisen from retrospectively processed data, obtained and
published from only a few (or single) centers with specialty
expertise in biomedical signal analytic techniques in TBI.
The European Union–based Collaborative European
NeuroTrauma Effectiveness Research in Traumatic Brain
Injury (CENTER-TBI) study has aimed to produce a unique
prospectively collected multi-center international TBI data set
[20]. The High-Resolution Intensive Care Unit (HR-ICU)
Sub-Study of CENTER-TBI has led to the creation of a
unique high-frequency physiologic data set for moderate/
severe TBI patients, allowing for a prospective multi-center
validation/exploration of previous single-center retrospective
findings. The goal of this specific study was to provide a
descriptive multi-center analysis of the cerebral physiologic
consequences of normal or elevated ICP, comparing those
with mean ICP values below 15 mmHg to those with mean
ICP values above 20 mmHg.
Methods
Patient population
All patients from the multi-center CENTER-TBI high-
resolution ICU monitoring cohort with parenchymal ICP
monitoring were included in this analysis. We further selected
only patients with a mean ICP value in the first 3 days of
recording either below 15 mmHg, or above 20 mmHg.
These two cohorts were selected so as to focus on the cohorts
of patients with grossly normal and abnormal ICP,
respectively.
Patients with EVD based ICP data were excluded given the
interrupted nature of their recordings. All patients were pro-
spectively recruited between January 2015 and December
2017 from 21 centers in the European Union (EU). All pa-
tients were admitted to ICU for their TBI during the course of
the study, with high-frequency digital signals recorded from
their ICU monitors during the course of their ICU stay. All
patients suffered predominantly from moderate to severe TBI
(moderate = Glasgow Coma Score (GCS) 9 to 12, and se-
vere = GCS of 8 or less). A minority of patients were catego-
rized at the time of admission as suffering from less severe
TBI, but experienced subsequent early deterioration leading to
ICU admission for care and monitoring. All patients in this
cohort had invasive ICP monitoring conducted in accordance
with the BTF guidelines [6].
Ethics
Data used in these analyses were collected as part of the
CENTER-TBI study which had individual national or local
regulatory approval; the UK Ethics approval is provided as an
exemplar: (IRAS No: 150943; REC 14/SC/1370). The
CENTER-TBI study (EC grant 602150) has been conducted
in accordance with all relevant laws of the EU if directly
applicable or of direct effect and all relevant laws of the coun-
try where the Recruiting sites were located including, but not
limited to, the relevant privacy and data protection laws and
regulations (the “Privacy Law”), the relevant laws and regu-
lations on the use of human materials, and all relevant guid-
ance relating to clinical studies from time to time in force
including, but not limited to, the ICH Harmonized Tripartite
Guideline for Good Clinical Practice (CPMP/ICH/135/95)
(“ICH GCP”) and the World Medical Association
Declaration of Helsinki entitled “Ethical Principles for
Medical Research Involving Human Subjects”. Informed con-
sent by the patients and/or the legal representative/next of kin
was obtained, accordingly to the local legislations, for all pa-
tients recruited in the Core Dataset of CENTER-TBI and doc-
umented in the e-CRF.
Data collection
As part of recruitment to the multi-center high-resolution ICU
cohort of CENTER-TBI, all patients had demographics and
injury data prospectively recorded. Similarly, all patients had
high-frequency digital signals from ICU monitoring recorded
throughout their ICU stay, with the goal of initiating recording
within 24 h of ICU admission. All digital ICU signals were
further processed (see Signal acquisition/Signal processing).
For the purpose of providing a description of the population
for this study, basic admission demographics and centrally
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reported CT variables for the first available CT of each patient
were extracted [23]. They included age, admission best GCS
motor score and pupillary reactivity (bilaterally reactive, uni-
lateral reactive, bilateral unreactive), Marshall CT
Classification, [21] Rotterdam CT score, [19] Helsinki CT
Score, [23] presence or absence of traumatic subarachnoid
hemorrhage (tSAH), extradural hematoma (EDH), pre-
hospital hypotension, and pre-hospital hypoxia. CENTER-
TBI data version 2.1 was accessed for the purpose of this
study, via Opal database software [13].
Signal acquisition
Arterial blood pressure (ABP) was obtained through arterial
lines connected to pressure transducers. ICP was acquired
from an intra-parenchymal strain gauge probe (Codman ICP
MicroSensor; Codman & Shurtleff Inc., Raynham, MA) and
parenchymal fiber optic pressure sensor (Camino ICP
Monitor; Integra Life Sciences, Plainsboro, NJ, United
States; https://www.integralife.com/). PbtO2 monitoring
occurred via invasive parenchymal monitoring (Licox probe;
Integra, Licox Brain Oxygen Monitoring System, Plainboro,
NJ), typically placed in the frontal lobe. All signals were
recorded using digital data transfer or digitized via an A/D
converter (DT9803; Data Translation, Marlboro, MA), where
appropriate; sampled at frequency of 100 Hz (Hz) or higher,
using the ICM+ software (Cambridge Enterprise Ltd.,
Cambridge, UK, http://icmplus.neurosurg.cam.ac.uk) or
Moberg CNS Monitor (Moberg Research Inc., Ambler, PA,
USA, https://www.moberg.com) or a combination of both.
Signal artifacts were removed using both manual and
automated methods prior to further processing or analysis.
Signal processing
Post-acquisition processing of the aforementioned signals was
conducted using ICM+ (Cambridge Enterprise Ltd.,
Cambridge, UK, http://icmplus.neurosurg.cam.ac.uk). CPP
was determined using the formula: CPP =MAP − ICP. Pulse
amplitude of ICP (AMP) was determined by calculating fun-
damental Fourier amplitude of the ICP pulse waveforms over
a 10-s window, updated every 10 s. Ten-second moving av-
erages (updated every 10 s to avoid data overlap) were calcu-
lated for all recorded signals: ICP, ABP (which produced
MAP), AMP, CPP, and PbtO2. This moving average filter
was applied to decimate the raw signals to a frequency range
association with the slow-wave vasogenic response.
We then derived ICP-based measures of cerebrovascular
reactivity, using the Pearson correlation between 30 consecu-
tive 10-s mean values of recorded physiology, updated every
minute. PRx was derived as the correlation between ICP and
MAP [12]. Pulse amplitude index (PAx) was derived as the
correlation between AMP and MAP [2]. Finally, RAC was
derived as the correlation (R) between AMP (A) and CPP (C)
[29]. RAP, an index of cerebral compensatory reserve, was
also derived as the correlation (R) between AMP (A) and ICP
(P) [5, 18].
Data were output in minute-by-minute update frequency
for the entire recording period. We then limited the data for
analysis to the first 3 days of recording in order to focus on the
acute phase commonly associated with cerebral physiologic
derangements. Finally, we filtered out patients with mean ICP
over the first 3 days of recording between 15 and 20 mmHg,
so as to focus on comparing cerebral physiology between
those with mean ICP < 15 mmHg, and those with mean ICP
> 20 mmHg. All data curation and processing occurred in R
(R Core Team (2019). R: A language and environment for
statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.
org/). Grand summary data for each patient, for the first
3 days of recording, were produced as follows:
1. Grand average values: ICP, CPP, MAP, AMP, PbtO2,
PRx, PAx, RAC, RAP
2. % Time above/below CPP thresholds: We determined the
percentage of time spent above BTF defined CPP thresh-
old of 70 mmHg, and below the threshold of 60 mmHg.
[6]
3. % Time below PbtO2 threshold of 20 mmHg. [22]
4. % Time above cerebrovascular reactivity critical
thresholds: We determined the percentage of time spent
above the following literature-defined PRx, PAx, and
RAC thresholds: [24, 31]
a. PRx: 0, + 0.25, + 0.35
b. PAx: 0, + 0.25
c. RAC: − 0.10, − 0.05
5. Mean hourly dose below PbtO2 of 20 mmHg.
6. Mean hourly dose above cerebrovascular reactivity crit-
ical threshold: See above for literature-defined critical
threshold utilized.
7. Area under RAP over time: Given complexities with
interpreting RAP, we determined the area under the
RAP over time curve for the RAP thresholds of 0 and +
0.4 (RAP AUC 0, and RAP AUC + 0.4), using a linear
interpolation method of integration. Such methodology
has been described previously by our group [34, 35].
Statistical analysis
All statistical analysis was performed using R statistical comput-
ing software. The focus of this studywas to provide a descriptive
exploratory analysis of differences in cerebral physiology be-
tween patients with low mean ICP (i.e., ICP < 15 mmHg) and
those with persistently high ICP (i.e., mean ICP > 20 mmHg).
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For continuous variables, Shapiro–Wilks test was used to test for
normality. For all statistical testing performed, alpha was set at
0.05, with no corrections for multiple comparisons undertaken
given the exploratory nature of this study.
Patient characteristics were summarized using mean, me-
dian, standard deviation, and inter-quartile range (IQR), where
appropriate. Box plots and histograms were produced to high-
light differences in characteristics and cerebral physiology,
between the < 15 and > 20 mmHg cohorts. Similarly, Mann–
WhitneyU andχ2 testing were utilized to compare differences
between these two cohorts, where applicable.
Finally, we briefly assessed differences in dichotomized 6-
month outcomes, usingχ2 testing. For this, GOSEwas dichot-
omized into both alive/dead, and favorable/unfavorable (fa-
vorable = lower moderate disability or better, unfavorable =
upper severe disability or worse). Further, to confirm the in-
dependent association between ICP and outcome, we evalu-
ated the association between ICP and dichotomized outcome
using multi-variable logistic regression models, adjusting for
admission characteristics (i.e., age, admission GCS motor
score, pupillary response, Marshall CT grade, and pre-
hospital hypoxia/hypotension). For such models, we reported
the area under the receiver operating curve (AUC), 95% con-
fidence intervals (CI), and p value. AUC and 95% CIs were
derived using a bootstrap process with 2000 iterations.
Results
Patient population characteristics
High-resolution physiologic recordings were available from
225 non-EVD patients. A total of 185 patients met the inclu-
sion criteria for this study from the CENTER-TBI HR-ICU
sub-study, with 157 displaying a mean ICP less than
15 mmHg and 28 with a mean ICP above 20 mmHg, during
the first 72 h of recording. For the group with ICP below
15 mmHg, the median age was 51 years (IQR 31 to
62.3 years), median admission GCS of 6 (IQR 3 to 7), and
122 males (77.7%). Similarly, the group with ICP above
20 mmHg had a median age of 54 years (IQR 35.3 to
68.3 years), median admission GCS of 7 (IQR 3 to 8), and
19 males (67.9%). Table 1 provides a detailed outline of the
patient demographics and admission characteristics for both
cohorts. Of note, Marshall and Rotterdam CT scores on ad-
mission were statistically worse in the ICP above 20 mmHg
group (p = 0.017 and p = 0.030, respectively).
Cerebral physiological consequences: ICP below
15 mmHg vs. ICP above 20 mmHg
Evaluating differences in cerebral physiologic responses be-
tween the two ICP non-overlapping cohorts, various patterns
were seen. Table 2 highlights all cerebral physiologic mea-
sures between both groups, and the results of Mann–
WhitneyU testing. The high ICP cohort displayed statistically
significant higher MAP (p = 0.0009), lower CPP (p < 0.0001),
and higher AMP (p < 0.0001). Mean PbtO2 was not different
between the two groups, though the mean hourly dose of
PbtO2 below 20 mmHg was significantly higher in the elevat-
ed ICP group (p = 0.033). Cerebrovascular reactivity, mea-
sured through PRx/PAx/RAC metrics, displayed statistically
higher mean (p < 0.004 for all), percentage of time above crit-
ical threshold (p < 0.004 for all), and mean hourly dose above
critical threshold (p < 0.004 for all). Similarly, worse compen-
satory reserve was also seen in the high ICP group, with trends
toward smaller integrated RAP AUC values. Figure 1 pro-
vides histogram representation of the percentage of time
above cerebrovascular reactivity thresholds for both groups.
Outcome differences: ICP below 15 mmHg versus ICP
above 20 mmHg
Comparing 6-month outcome between the two ICP extreme
groups, there was a clear association between persistent ICP
elevations (i.e., ICP above 20 mmHg) and worse outcome.
Figure 2 provides a histogram of the GOSE scores for both
the ICP below 15 mmHg (Fig. 2a) and the ICP above
20 mmHg (Fig. 2b) groups. This figure highlights the dispar-
ity of outcomes based on this ICP dichotomization. Similarly,
evaluating differences in dichotomized GOSE outcomes at
6 months, there is a statistically higher mortality (p < 0.0001)
and unfavorable outcome (p = 0.014), using χ2 testing. The
independent association of ICP with outcome has previously
been explored in the CENTER-TBI HR-ICU sub-study cohort
[33]. To confirm that this relationship holds true in the cohort
described in this manuscript, we evaluated the association
between mean ICP and dichotomized outcomes using multi-
variable logistic regression models, adjusting for baseline ad-
mission characteristics (see Methods for list of characteris-
tics). For the association with mortality, ICP maintained an
independent association (p = 0.0005), when adjusting for
baseline admission characteristics (AUC = 0.801, 95% CI
0.716–0.884 for full model). However, for association with
unfavorable outcome, mean ICP failed to maintain signifi-
cance (p = 0.126) when adjusting for baseline admission char-
acteristics (AUC = 0.678, 95% CI 0.584–0.762, for full
model).
Discussion
Using the CENTER-TBI HR-ICU sub-study data set, we have
been able to provide some prospective multi-center validation
for previously described cerebral physiologic responses to
ICP extremes. Some important aspects deserve highlighting.
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First, sustained elevations in ICP in the current era of critical
care management of TBI patients are rare. Out of the 225 non-
EVD ICPmonitored patients from the HR-ICU cohort, only 28
had sustained elevations in ICP to generate a 3-daymean above
20 mmHg. The vast majority (n = 157) had a mean ICP below
15 mmHg. This speaks to the active treatments received by
these patients during the course of their ICU care and highlights
the successes of aggressive care [6, 14, 16, 32].
Second, comparing those patients with mean ICP below
15 mmHg, versus above 20 mmHg, the only apparent differ-
ence in admission demographics/characteristics were the ad-
mission CT grade, both Marshall and Rotterdam. There was
no difference in other admission factors between these two
cohorts. This emphasizes the association between primary in-
jury pattern/severity and impaired cerebral physiology [17,
30, 35, 36]. Such findings corroborate previous retrospective
results.
Third, 6-month outcomes were worse in those with a 3-day
mean ICP above 20 mmHg. In particular, the association with
6-month mortality was much stronger than that of unfavorable
outcome. This has been described previously, where ICP ap-
pears to be a stronger predictor of mortality over functional
outcome post-TBI [6, 24]. This held true in multi-variable
logistic regression analysis, adjusting for baseline admission
characteristics. Such worse outcomes are likely driven not
only by ICP alone but by a myriad of cerebral physiologic
derangements. It must be acknowledged that increased ICP
may not in itself lead to poor outcome in TBI but may just
be an indicator of overall injury severity and globally impaired
homeostasis, which is difficult to correct and may in turn drive
poor outcomes. This is further supported by the percentage of
time with CPP below 60 mmHg and above 70 mmHg, where
the ICP > 20 mmHg cohort had significantly higher propor-
tion of time with CPP below 60 mmHg. Conversely, in the
normal ICP group, only slightly less than a half of patients had
favorable outcome. It means that apart from intracranial hy-
pertension, other factors may be responsible for worse out-
come. One of them, as identified previously, is deterioration
in cerebrovascular reactivity [12, 14, 24, 33]. Finally, if de-
ranged homeostasis is the true driver of poor outcomes in TBI,
the concept of therapeutic fatigue becomes relevant, where
persistent ICP elevations despite active attempts to treat may
lead to situations where the treating team is more prone to de-
escalating care over concerns of futility. Such attitudes toward
certain physiologic responses may influence the statistical re-
lationships seen and are difficult to account for.
Fourth, brain tissue oxygenation trended toward lower
values in those with elevated ICP. This was seen in percentage
Table 1 Patient admission demographics, injury and outcome data—Mann–WhitneyU/χ2 testing—ICP below 15mmHg versus ICP above 20mmHg
Demographic variable Mean ICP below 15 mmHg Mean ICP Above 20 mmHg Mann–Whitney U/χ2
p value
N = 157 N = 28
Median IQR Median IQR
Age (years) 51 31–62.3 54 35.3–68.3 0.311
Sex (male) 122 NA 19 NA 0.385
Admission total GCS 6 3–7 7 3–8 0.611
Admission GCS motor 4 1–5 3 2–4 0.263
Pupillary response 0 117 NA 18 NA NS**
1 13 2
2 27 8
Pre-hospital hypoxia 21 NA 7 NA 0.201
Pre-hospital hypotension 22 NA 1 NA 0.215
Admission Marshall CT grade 3 2–6 6 3–6 0.017
Admission Rotterdam CT grade 3 3–4 4 3–5 0.030
Admission Helsinki CT grade 4 2–6 6 3–9 0.149
Epidural lesion 29 NA 7 NA 0.240
Traumatic subarachnoid hemorrhage 100 NA 14 NA 0.900
Alive at 6 months* 119 NA 9 NA <0.0001
Favorable outcome at 6 months* 64 NA 5 NA 0.014
Favorable outcome = based on dichotomized 6-month Glasgow Outcome Score Extended (favorable = 5 or higher, unfavorable = 4 or less), GCS =
Glasgow Coma Scale, IQR = interquartile range, N = number of patients, NA = not applicable. Note: pupillary response graded according to 0 =
bilaterally reactive, 1 = unilateral unreactive, 2 = bilaterally unreactive; p values reaching statistical significance (< 0.05) are bolded
*20 patients did not have a 6-month outcome available
**All χ2 testing between various groupings of pupillary response failed to reach statistical significance
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of time with PbtO2 below 20 mmHg, where there was a trend
toward lower mean and higher percentage of time below
threshold in the ICP above 20 mmHg group. Similarly, eval-
uating the mean hourly dose of PbtO2 below 20 mmHg, there
was a statistically significant highmean hourly dose in the ICP
above 20 mmHg group. This highlights previously described
relationships between ICP and extracellular oxygen. Such
findings, as well as literature supporting the association of
low PbtO2 and normal ICP with poor outcome in TBI, have
sparked the phase II and ongoing phase III trials for PbtO2-
directed therapy in TBI [7, 22]. It must be emphasized, how-
ever, that these findings do not suggest a specific directional
Table 2 Cerebral physiologic data—Mann–Whitney U testing—ICP below 15 mmHg versus ICP above 20 mmHg
Demographic variable Mean ICP below 15 mmHg Mean ICP above 20 mmHg Mann–Whitney U
p value
N = 157 N = 28
Median IQR Median IQR
ICP (mmHg) 11.0 8.2–12.9 23.4 21.9–37.3 <0.0001
MAP (mmHg) 82.0 76.2–87.5 89 80.2–96.8 0.0009
CPP (mmHg) 71.8 66.2–77.6 59.1 50.0–73.1 <0.0001
AMP (mmHg) 1.9 1.4–2.7 3.5 2.2–5.6 <0.0001
PbtO2 (mmHg)* 27.0 23.2–33.1 22.1 18.2–26.2 0.183
PRx (a.u.) − 0.002 − 0.118 to 0.014 0.206 − 0.009 to 0.582 0.0006
PAx (a.u.) − 0.090 − 0.208 to 0.095 0.151 − 0.090 to 0.376 0.0001
RAC (a.u.) − 0.384 − 0.554 to − 0.176 − 0.181 − 0.382 to 0.145 0.003
RAP (a.u.) 0.731 0.560–0.837 0.710 0.485–0.783 0.290
RAP AUC 0 2662.2 1908.0–3369.3 2194.0 1000.0–3198.9 0.047
RAP AUC+ 0.4 1305.6 716.4–1764.6 964.0 245–1565.8 0.052
Total length of recording (h) 119.7 80.5–161.6 114.1 57.1–167.7 0.333
% Time above/below threshold
Below CPP 60 mmHg 7.3 2.2–26.3 57.2 12.4–75.4 <0.0001
Above CPP 70 mmHg 53.0 30.6–81.2 12.7 3.5–55.5 0.0001
Above PRx 0 47.8 22.6–64.3 72.4 47.1–90.2 0.0009
Above PRx + 0.25 23.7 14.0–38.0 46.1 26.2–82.1 0.0003
Above PRx + 0.35 17.0 9.7–28.0 36.4 18.3–77.9 0.0003
Above PAx 0 39.6 25.6–59.9 66.4 41.4–79.6 0.0002
Above PAx + 0.25 16.0 8.8–32.1 36.4 19.2–62.6 <0.0001
Above RAC − 0.10 20.9 9.2–40.4 39.4 18.1–75.1 0.003
Above RAC − 0.05 17.6 7.8–35.4 35.3 15.9–71.2 0.002
Below PbtO2 20 mmHg* 16.5 1.7–35.1 30.7 19.3–54.3 0.229
Mean hourly dose above/below threshold
Above PRx 0 7.5 4.9–11.3 12.5 6.2–26.9 0.003
Above PRx + 0.25 2.9 1.7–4.4 6.0 2.5–16.1 0.0006
Above PRx + 0.35 1.8 1.1–2.9 4.1 1.6–12.3 0.0004
Above PAx 0 5.0 2.9–9.5 10.3 5.9–17.3 0.0003
Above PAx + 0.25 1.6 0.7–3.4 4.3 2.3–8.6 <0.0001
Above RAC − 0.10 2.6 1.1–5.4 5.8 2.1–15.8 0.001
Above RAC − 0.05 2.0 0.8–4.0 4.9 1.8–13.7 0.0007
Below PbtO2 20 mmHg* 3.1 0.3–55.2 94.8 49.9–144.1 0.033
p values reaching statistical significance (<0.05) are bolded
a.u. = arbitrary units, AUC = integrated area under the RAP over time plot, AMP= pulse amplitude of ICP, CPP = cerebral perfusion pressure, ICP =
intracranial pressure, IQR = interquartile range, MAP =mean arterial pressure, mmHg =millimeters of mercury, N = number of patients, PbtO2 = brain
tissue oxygen, PAx = pulse amplitude index (correlation between AMP and CPP), PRx = pressure reactivity index (correlation between ICP andMAP),
RAC = correlation between AMP and CPP
*Only 47 patients (41 in the ICP < 15 mmHg, and 6 in the > 20 mmHg cohorts) had PbtO2 monitoring
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causality between ICP and PbtO2, but only provide evidence
in support of an association.Much further multi-center work is
required, investigating the temporal causal relationships be-
tween various aspects of cerebral physiology.
Fifth, ICP elevations are associated with worse cerebrovas-
cular reactivity. This was seen measuring cerebrovascular re-
activity using PRx, PAx, and RAC. Regardless of which in-
dex was assessed, there was a statistically significant high
mean, percentage of time above threshold, and mean hourly
dose above threshold in the ICP above 20 mmHg group. This
held true for every index threshold tested for PRx, PAx, and
RAC. This finding validates previous retrospective single-
center findings that ICP elevations are associated with worse
cerebrovascular reactivity [1, 10]. However, another interest-
ing finding in this study is that those with ICP below
15 mmHg still had a median percentage of time with PRx
above 0 and + 0.25 of 47.8 (IQR 22.6–64.3) and 23.7 (IQR
14.0–38.0), respectively. This suggests that despite ICP con-
trol, moderate/severe TBI patients still display significant time
periods in the first 3 days of care with impaired cerebrovascu-
lar reactivity. Recent work has highlighted the association
between impaired cerebrovascular reactivity and outcome, as
Fig. 1 Histograms for % time above cerebrovascular reactivity threshold.
AMP = pulse amplitude index, CPP = cerebral perfusion pressure,
Frequency = number of patients, ICP = intracranial pressure, MAP =
mean arterial pressure, PAx = pulse amplitude index (correlation
between AMP and MAP), PRx = pressure reactivity index (correlation
between ICP and MAP), RAC = correlation between AMP and CPP. a
Histogram of % time with PRx above + 0.25–ICP < 15 mmHg group. b
Histogram of % time with PRx above + 0.25–ICP > 20 mmHg group. c
Histogram of % time with PAx above +0.25–ICP < 15 mmHg group. d
Histogram of % time with PAx above + 0.25–ICP > 20 mmHg group. e
Histogram of % time with RAC above − 0.05–ICP < 15 mmHg group. f
Histogram of % time with RAC above − 0.05–ICP > 20 mmHg group
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well as its apparent independence to current BTF-based ther-
apeutic interventions for TBI [14, 32]. The findings in this
study indicate the need for cerebrovascular reactivity–based
interventions, regardless of ICP control, so as to prevent on-
going secondary injury related to impaired cerebral autoregu-
lation. Such work is the focus of various collaborative efforts
globally [4, 20, 37]. However, it must be emphasized that the
results here are merely associations, and do not prove causal-
ity in the relationships between ICP elevations and impaired
cerebrovascular reactivity. Further investigation into the tem-
poral profiles of cerebral physiology responses are required.
Finally, cerebral compensatory reserve, as measured
through RAP and its integrated AUC above 0, was found to
be worse in those with ICP above 20 mmHg. Given that the
relationship between RAP and ICP is an inverse U relation-
ship, we utilized the integrated AUC to characterize the insult
burden of RAP over time. As ICP remains elevated, RAP
transitions from + 1 (impaired compensatory reserve) toward
0 and eventually a negative number (indicating severe intra-
cranial hypertension and associated collapse of cerebral arte-
rioles, disturbing integrity of cerebral blood flow). The inte-
grated AUC above 0 was found to be significantly lower (p =
0.047) in the ICP > 20mmHg cohort, indicating worse overall
compensatory reserve. These findings are the first multi-center
international findings to validate previous single-center retro-
spective work on RAP in TBI [5]. However, again, these
findings do not support a directional causal relationship be-
tween ICP and RAP, but merely an association. Further inves-
tigation into the use of continuously updating RAP monitor-
ing in TBI is required.
Limitations
Despite the interesting results found, there are some signifi-
cant limitations of this study which deserve highlighting. First,
this is a multi-center cohort of TBI patients receiving active
ICP- and CPP-directed therapy. Thus, the impact of various
interventions on recorded cerebral physiology cannot be
accounted for. Such interventions will have impacted the
physiology recorded. As such, the physiology does not repre-
sent the natural history of moderate/severe TBI.
Second, despite being multi-center and international in na-
ture, our data set is still relatively small, with only 157 patients
in the below 15mmHg and 28 in the above 20mmHg cohorts,
respectively. As such, despite providing some validation for
previous single-center retrospective works, the results here
should still be considered exploratory in nature. Thus, the
reported findings between different cerebral physiologic mea-
sures and ICP merely represent associations and do not pro-
vide evidence supporting any directional causal relationship at
this time. Future work in the field of multi-modal cerebral
physiologic monitoring necessitates widespread multi-center
data collection initiatives, to generate larger data sets.
Third, given this was an exploratory project with a relative-
ly small data set, we did not correct for multiple comparisons.
Some of the described “significant” results would not have
been significant if such correction were taken into account,
particularly PbtO2 and RAP AUC above 0. Thus, the reported
statistically significant results need to be interpreted with cau-
tion and as exploratory at this time, as they represent prelim-
inary associations only.
Finally, given this is one of the first multi-center prospec-
tive data sets with high-frequency physiology to analyze, we
focused primarily on descriptive analysis of the difference
between extreme ICP cohorts. The complex interaction be-
tween various multi-modal monitoring cerebral physiology
(raw or derived) cannot be commented on here. Such work
requires extensive data sets with numerous invasive/non-
invasive monitors simultaneously recording in every patient.
Only then can statements be made regarding the in vivo tem-
poral relationship between various cerebral physiologic mea-
sures. The HR cohort from CENTER-TBI does not have large
numbers of such multi-modal data. This is highlighted by the
relatively small number of PbtO2 patients in this study (n =
47). Therefore, as commented on previously, the reported re-
lationships between ICP elevation and other aspects of cere-
bral physiology only represent associations and do not imply
causality. Future investigation into the temporal and direction-
al causal relationships between ICP and other aspects of multi-
Fig. 2 Histogram of 6-month GOSE–ICP below 15 mmHg (a) and ICP
above 20 mmHg cohort (b). Frequency = number of patients, GOSE =
Glasgow Outcome Score Extended. a Mean ICP < 15 mmHg cohort. b
Mean ICP > 20 mmHg cohort
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modal cerebral physiologic monitoring will require the appli-
cation of advanced time-series techniques. Such work would
include the use of linear/non-linear mixed modeling tech-
niques, incorporating individual signal Box–Jenkin’s
autoregressive integrative moving average (ARIMA) struc-
tures, development of multivariate vector autoregressive mov-
ing average (VARMA) models with impulse response func-
tion plots, as well as Granger causality testing [25, 27, 28]. As
the focus of this study was to provide preliminary multi-center
descriptions of the relationships between multi-modal cerebral
physiology during ICP extremes, this advance time-series
modeling is beyond the scope of this paper. Such complex
work with multi-center data sets are the focus of ongoing
collaborative initiatives in TBI research both in Europe [20]
and Canada [4].
Conclusions Extremes in ICP during the first 72 h after
moderate/severe TBI are associated with significant dispar-
ities in CPP, AMP, cerebrovascular reactivity, cerebral com-
pensatory reserve, and brain tissue oxygenation metrics. Such
ICP extremes appear to be strongly related to 6-month patient
outcomes, in keeping with previous literature. This work pro-
vides multi-center validation for previously described single-
center retrospective results.
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